^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Pancreatic Adenocarcinoma
    Drug:Krazati (adagrasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    05/04/2023
    Excerpt:
    Pancreatic Adenocarcinoma….PRINCIPLES OF SYSTEMIC THERAPY….Useful in Certain Circumstances...Adagrasib (if KRAS G12C mutation positive)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    Excerpt:
    KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.